Abstract
Stavudine, 2′,3′-didehydro-3′-deoxythymidine (D4T), has recently been approved by the U.S. Food and Drug Administration for the treatment of advanced HIV-1 infection in adults who are 1) intolerant to approved therapies with proven clinical benefit, or 2) have experienced significant clinical or immunologic deterioration while receiving these therapies, or 3) for whom such therapies are contraindicated. Approval was based on studies in over 11,000 patients, almost all of whom had received prior zidovudine therapy, showing that stavudine had a beneficial effect upon surrogate markers and acceptable toxicity. The effect of stavudine in delaying progression of HIV disease awaits the completion of clinical trials which are currently in progress.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
August EM, Birks EM, Prusoff WH. 3’-Deoxythymidin-2 ` -ene permeation of human lymphocyte H9 cells by non-facilitated diffusion. Mol. Pharmacol. 1991; 39: 246–249.
Ho H-T., Hitchcock MJM. Cellular pharmacology of 2’, 3’–dideoxy-2’, 2’–didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob. Agents Chemother. 1989; 33: 844–849.
Riddler SA, Anderson RE, Mellors JW. Antiretroviral Activity of Stauvudine (2’, 3’-didehydro-3’deoxythynidine, D4T) J. Antiviral Research (in press).
Lin T-S, Schinazi RF, Prusoff WH. Potent and selective in vitro activity of 3’–deoxythymidin-2’–ene (3’–deoxy-2’, 3’ -didehydrothymidine) against human immunodeficiency birus. Biochem. Pharmacol. 1987; 36: 2713–2718.
Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243. 1731–1734.
Lacey SF, Larder BA. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2’, 3’–didehydro-2’, 3’–dideoxythymidine in cell culture. Antimicrob. Agents Chemother. 1994; 38: 1428–1432.
Larder BA, Chesebro B, Richman DD. Susceptibilities of zidouvudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob. Agents Chemother 1990; 34: 436–441.
Richman DD. Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus. Am. J. Med. 1990; 99 (Suppl 5B), 8S - 10S.
Mellors JW, Dutschman GE, Im GJ, Tramontano E, Winkler SR, Cheng Y-C. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mo 1. Pharmacol. 1992; 41: 446–451.
Brankovan V, Tarantini K, Datema R, Chou TC. Strong synergistic anti-HIV activity of a purine and a pyrimidine nucleoside analog, ddI and d4T. V International Conference of AIDS, Montreal 1991; Abstract M.C.P. 128.
Sorensen AM, Nielsen C, Evaluation of the combination effect of different antiviral compounds against HIV in vitro. Scandanavian J Infect Dis 1993; 25: 365–371.
Denman SL, Dunkle LM, Kaul S, McLaren C, Skowron G, Kouttab NM, Kennedy TA, Weitberg AB, Curt GA. 2’, 3’–Didehydro-3’–deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: A phase I trial. J. Infect. Dis. 1993; 167: 21–29.
Browne MJ, Mayer KH, Chafee SBD, Dudley MN, Graham KK, Kaul S, Geletko S, Dunkle L, Browne M, Mayer K. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J. Infect. Dis. 1992; 166: 480–485.
Kim GP, Brett-Smith H, Friedland GH, Chang CP, Griffith B, Prusoff W, Cheng YC, Toxicity and Pharmacokinetics of 2’3’ didehydro 3’deoxy thymidine (D4T) at low/moderate doses, 32 1CAAC, Anaheim Calif., 1992, Abstr. no. 561.
Brett-Smith H, Griffith B, Kim G, Walesky M, Friedland G. Magintude and duration of stavudine antiretroviral effect. First National Conference of Human Retroviruses and related Infections, Washington D.C., Dec. 1993.
Dunkle L, Anderson R, McLarin C et al, Stavudine: A Promising Anti-retroviral Agent VIII International Conference on AIDS, Amsterdam, 1992, Abstr. WEB 1011.
Dunkle LM, Pavia A, Messina M, Cross A, The BMS-019 Study Group, Stavudine (d4t) vs. zidovudine (ZDV) for the treatment of HIV-infected patients wit CD4 counts of 50-S00cells/mm3 following at least 6 months zidovudine, 34th ICAAC, Orlando Fla. 1994.
Smaldone L. Personal Communication.
Lin PF, Samanta H, Rose RE, Patrick AK, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994; 170: 1157–64.
Gonzalez C, Cheng YC, Griffith B, Friedland G, (unpublished).
Anderson RE, et al. Response to Stavudine (d4t) in Zidovudine naive subjects, 34th ICAAC, Orlando Fla. 1994.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Friedland, G., Dunkle, L.W., Cross, A.P. (1996). Stavudine (d4T, Zerit®). In: Mills, J., Volberding, P.A., Corey, L. (eds) Antiviral Chemotherapy 4. Advances in Experimental Medicine and Biology, vol 394. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9209-6_24
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9209-6_24
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9211-9
Online ISBN: 978-1-4757-9209-6
eBook Packages: Springer Book Archive